Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | HTR1B | P28222 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4784837 | 1.00 | HTR1D (1.00) | HTR1DHTR1AHTR1BCYP1A2KDM4E | |
| SCHEMBL30058389 | 1.00 | HTR1D (1.00) | HTR1DHTR1AHTR1BCYP1A2KDM4E | |
| SCHEMBL4785846 | 0.95 | CYP3A4 (0.90) | HTR1DHTR1AHTR1BCYP1A2KDM4E | |
| SCHEMBL4785841 | 0.95 | CYP3A4 (0.90) | HTR1DHTR1AHTR1BCYP1A2KDM4E | |
| SCHEMBL4787569 | 0.92 | CYP1A2 (0.85) | HTR1DHTR1AHTR1BCYP1A2KDM4E | |
| SCHEMBL4787574 | 0.92 | CYP1A2 (0.85) | HTR1DHTR1AHTR1BCYP1A2KDM4E | |
| SCHEMBL4787970 | 0.91 | CYP3A4 (0.83) | HTR1DHTR1AHTR1BCYP1A2KDM4E | |
| SCHEMBL4787979 | 0.91 | CYP3A4 (0.83) | HTR1DHTR1AHTR1BCYP1A2KDM4E | |
| SCHEMBL18622645 | 0.90 | HTR1A (0.81) | HTR1DHTR1AHTR1BCYP1A2KDM4E | |
| SCHEMBL4784967 | 0.89 | HTR1A (0.80) | HTR1DHTR1AHTR1BCYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-06-23 | — | — | US | claimed |
| US-20170071949-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2017-03-16 | — | — | US | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| US-12551481-B2 | Molecular targets for addiction | THE JACKSON LABORATORY (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4673443-A1 | METHODS AND COMPOSITIONS FOR TREATING COCAINE ADDICTION | The Jackson Laboratory (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182590-A1 | METHODS AND COMPOSITIONS FOR TREATING COCAINE ADDICTION | THE JACKSON LABORATORY (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20230057844-A1 | MOLECULAR TARGETS FOR ADDICTION | THE JACKSON LABORATORY (US) | 2023-02-23 | — | — | US | disclosed |
| US-11478476-B2 | Use of buspirone metabolites | CONTERA PHARMA APS (DK) | 2022-10-25 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| WO-2008118445-A9 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | PROMEGA CORP (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008118445-A9 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | PROMEGA CORP (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080248511-A1 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | PROMEGA CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080248511-A1 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | PROMEGA CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080248511-A1 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | PROMEGA CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2008118445-A1 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | PROMEGA CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118445-A1 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | PROMEGA CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | HTR1D 35/4885HTR1A 4/4885HTR1B 6/4885 |
| US-20080248511-A1 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | GLO1, ESD, GLB1 | HTR1D 3214/4885HTR1A 2628/4885HTR1B 2708/4885 |
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | HTR1D 14/4885HTR1A 6/4885HTR1B 4/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | HTR1D 46/4885HTR1A 6/4885HTR1B 13/4885 |
| US-12551481-B2 | Molecular targets for addiction | HTR1D, HTR2A, HTR1A | HTR1D 1/4885HTR1A 3/4885HTR1B 8/4885 |
| US-20170071949-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | HTR1D 14/4885HTR1A 6/4885HTR1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.